With philanthropic support from Never Surrender Inc., Essentia Health will become one of about 50 sites participating in the HEALEY ALS Platform Trial, an initiative led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) and the Northeast ALS Consortium (NEALS). This groundbreaking perpetual study opened for enrollment in July 2020 and aims to accelerate the development of effective treatments for ALS, or amyotrophic lateral sclerosis.
This year marks the 20th of up to $5,000 in Joseph W. Mayo ALS Scholarships being awarded to Maine men and woman attending traditional and nontraditional educational programs in memory of Mayo, a former state representative from Thomaston.
The results of research by scientists at the University of Edinburgh and at the University of Oxford have found that a drug typically used to treat enlarged prostates and high blood pressure could also have promise as a potential new therapy for amyotrophic lateral sclerosis (ALS), the most prevalent form of motor neuron disease (MND).
In July, Huet and his partner, Brian Hubert, received a Christmas in July gift that was full of gift cards. It was something that would cover groceries. It was just something that helped.
A gene therapy, patented through the University of California, San Diego (UCSD) and the Department of Veterans Affairs (and licensed to Eikonoklastes Therapeutics), measurably delayed disease onset in humanized mouse and rat models of familial amyotrophic lateral sclerosis (ALS).
After recently receiving approval in Canada, AMX0035 looks to join the US market alongside riluzole and edaravone, the only FDA-approved therapeutics that slow disease progression in ALS.
Wichterle’s unlikely journey from basic scientist to drug developer began when he discovered how to efficiently create functional spinal motor neurons in a laboratory dish from embryonic stem cells.